Abstracts tagged "osteoporosis"

Abstract Number: 2730 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Romosozumab vs Placebo Among Patients with Mild-to-Moderate Chronic Kidney Disease
Paul Miller¹, Arkadi Chines ², Ben-Hur Albergaria ³, Evelien Gielen ⁴, Bente Langdahl ⁵, Akimitsu Miyauchi ⁶, Mark Vanderkelen ⁷, Cassandra Milmont ², Judy Maddox ² and Jonathan Adachi ⁸, ¹Colorado Center for Bone Research at Panorama Orthopedics and Spine Center, Golden, CO, ²Amgen Inc., Thousand Oaks, CA, ³Federal University of Espirito Santo, Vitória, Brazil, ⁴Gerontology and Geriatrics, Department of Chronic Diseases, Metabolism and Aging, KU Leuven & Center for Metabolic Bone Diseases, UZ Leuven, Leuven, Belgium, ⁵Aarhus University Hospital, Aarhus, Denmark, ⁶Miyauchi Medical Center, Osaka, Japan, ⁷UCB Pharma, Brussels, Belgium, ⁸McMaster University and St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada
Background/Purpose: Osteoporosis and renal insufficiency are coexisting disease states in a substantial proportion of postmenopausal women. Since bisphosphonates are generally contraindicated in patients with estimated…
Abstract Number: 1192 • 2019 ACR/ARP Annual Meeting
Effect of a Clinical Decision Support System on a Quality Indicator of Glucocorticoid-induced Osteoporosis and Trends of Drug Treatment in a Japanese Hospital
Hiroki Ozawa¹, Sho Fukui ¹, Genki Kidoguchi ¹, Takehiro Nakai ², Satoshi Kawaai ¹, Ayako Koido ¹, Yukihiko Ikeda ¹, Masei Suda ¹, Haruyuki Yanaoka ¹, Hisanori Shimizu ¹, Hiromichi Tamaki ¹, Tokutaro Tsuda ¹, Mitsumasa Kishimoto ³, Kenichi Yamaguchi ¹ and Masato Okada ¹, ¹St.Luke International Hospital Immuno-Rheumatology Center, Tokyo, Japan, ²St.Luke International Hospital Immuno-Rheumatology Center, Tokyo, Tokyo, Japan, ³Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan
Background/Purpose: Glucocorticoid-induced osteoporosis (GIOP) is a common, preventable and treatable complication of glucocorticoid therapy. We defined quality indicator (QI) for GIOP and took a hospital-wide…
Abstract Number: 2214 • 2019 ACR/ARP Annual Meeting
Assessment of Bone Quality by Trabecular Bone Score (TBS) in Systemic Lupus Erythematosus Patients
Andrea Casabella ¹, Sabrina Paolino ², Alberto Sulli³, Elisa Alessandri ⁴, Vanessa Smith ⁵, Barbara Ruaro ⁶, Carmen Pizzorni ² and Maurizio Cutolo ⁷, ¹1 Research Laboratory and Academic Division of the Clinical Rheumatology Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, ³Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genoa, Italy, ⁴Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genova, ⁵Dept. of Rheumatology, Ghent University Hospital, Ghent, Belgium; Dept. of Internal Medicine, Ghent University, Ghent, Belgium; Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center (IRC), Ghent, Belgium, Gent, Belgium, ⁶1 Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy; 2 Cardinal Ferrari Centre, S. Stefano Rheabilitation, Fontanellato (Parma), Italy, Genoa, Italy, ⁷Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genoa, Italy
Background/Purpose: Systemic lupus erythematosus (SLE) patients show an increased risk of low bone mass as a result of multifactorial events: physical inactivity, persistent inflammation, low…
Abstract Number: 1333 • 2019 ACR/ARP Annual Meeting
The Comparative Risk of Osteoporotic Fractures Among Patients with Rheumatoid Arthritis Receiving TNF Inhibitors versus Other Biologics: A Nation-wide Cohort Study in Korea
Eun Hye Park¹, Anna Shin ², Yaa-Hui Dong ³, You-Jung Ha ¹, Yun Jong Lee ⁴, Eun Bong Lee ⁵, Yeong-Wook Song ⁶ and Eun Ha Kang ¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, Seongnam, Republic of Korea, ²Seoul National University Bundang Hospital, Seongnam, Republic of Korea, ³Graduate Institute of Epidemiology and Preventive Medicine, National Taiwan University, Taipei, Taiwan (Republic of China), ⁴Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, Seongnam, Republic of Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, seoul, ⁶Seoul National University Hospital, Seoul, Republic of Korea
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of osteoporosis and osteoporotic fracture, but little is known about comparative risk of osteoporotic fractures between…
Abstract Number: 2215 • 2019 ACR/ARP Annual Meeting
Modeling-Based Bone Formation Persists in the Femoral Neck Despite Remodeling Inhibition in Subjects Treated with Denosumab
David Dempster¹, Peter Butler ², Mathias Bostrom ³, Jeri Nieves ¹, Hua Zhou ⁴, Li Chen ², Nicola Pannacciulli ², Rachel Wagman ² and Felicia Cosman ¹, ¹Columbia University, New York, NY, ²Amgen Inc., Thousand Oaks, CA, ³Hospital for Special Surgery, New York, NY, ⁴Helen Hayes Hospital, West Haverstraw, NY
Background/Purpose: Denosumab (DMAb) is a potent antiresorptive agent, but findings in non-human primates suggest that modeling-based bone formation (MBBF) may persist despite DMAb treatment (Ominsky…
Abstract Number: 1872 • 2019 ACR/ARP Annual Meeting
Worsening Trends in Osteoporosis Management in the Medicare Population: 2010-2014
Jeffrey Curtis¹, Shanette G. Daigle ², Setareh A. Williams ³, Richard Weiss ³, Yamei Wang ⁴ and Tarun Arora ², ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, ³Radius Health, Inc, Waltham, ⁴Radius Health, Inc, Waltham
Background/Purpose: Osteoporotic fractures are an important public health burden, and with an increasing aging population, the number of Americans at risk of fractures is projected…
Abstract Number: 2216 • 2019 ACR/ARP Annual Meeting
Bone Mineral Density of the Spine, Hip, and Distal Radius in Patients with Postmenopausal Osteoporosis
KEN NAKASEKO¹, ¹Department of Orthopaedic Surgery and Rheumatology Kuwana City Medical Center, kuwana mie, Japan
Background/Purpose: Bone mineral density (BMD) is used for the diagnosis of osteoporosis, predicting future fracture risk, and monitoring osteoporosis treatment. Osteoporosis is defined as BMD…
Abstract Number: 1633 • 2018 ACR/ARHP Annual Meeting
Fragility Fractures in Psoriatic Arthritis Patients: A Matched-Control Study
Luciano Fernando Lo Giudice¹, Marina Scolnik², Florencia Pierini³, Nicolas Martin Marin Zucaro¹, John Fredy Jaramillo Gallego¹ and Enrique R Soriano², ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Capital Federal, Argentina, ²Rheumatology Unit, Internal Medicine Service. Hospital Italiano Buenos Aires. Argentina, Buenos Aires, Argentina, ³Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, CABA, Argentina
Background/Purpose: patients with Psoriatic Arthritis (PsA) in spite of having bone production as one of their characteristic features, very often have osteoporosis, but scarce data…
Abstract Number: 2182 • 2018 ACR/ARHP Annual Meeting
Defining Alendronate Drug Holidays and Re-Initiation in US Medicare Data
Ayesha Jaleel¹, Jeffrey R. Curtis², Rui Chen², Huifeng Yun³, Phillip J. Foster⁴, Nicole Wright³, Tarun Arora², Amy S. Mudano², Suzanne Cadarette⁵ and Kenneth Saag², ¹Internal Medicine, Baptist Brookwood Health, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁴Department of Medicine, Division of Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada
Background/Purpose: Given alendronate’s (ALN) prolonged skeletal retention and emerging safety concerns, the ASBMR task force recommended consideration of a “drug holiday” after 5 years of…
Abstract Number: 2309 • 2018 ACR/ARHP Annual Meeting
Implementation of a Primary Prevention, Population-Based Virtual Osteoporosis Clinic Dramatically Increases the Number of Rural Veterans Receiving Osteoporosis Screening and Treatment
Karla L. Miller¹, Shardool Patel², Grant W. Cannon³ and Zachary L. Anderson², ¹Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Salt Lake City VA Medical Center, Salt Lake City, UT, ³Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT
Background/Purpose: The delivery of osteoporosis services is sub-optimal nationally and throughout the Veterans Affairs (VA) healthcare system and particularly poor for rural Veterans. To meet…
Abstract Number: 2319 • 2018 ACR/ARHP Annual Meeting
Adherence to Guideline Recommendations for Screening and Treatment of Glucocorticoid Induced Osteoporosis in Patients with Rheumatoid Arthritis on Long Term Glucocorticoid Therapy at a Tertiary Care Center
Patrick Webster¹ and Tarun S. Sharma², ¹Internal Medicine, Allegheny Health Network, Pittsburgh, PA, ²Rheumatology, Lupus Center of Excellence, Allegheny Health Network, Pittsburgh, PA
Background/Purpose: Glucocorticoid induced osteoporosis (GIOP) is an under-recognized and under-treated condition. Many long-term glucocorticoid (GC) users never receive therapy to prevent bone loss or are…
Abstract Number: 2323 • 2018 ACR/ARHP Annual Meeting
Predictors of Mortality in Patients with Hip Fragility Fracture
Miguel Guerra¹, Sara Ganhão^2,3, Francisca Aguiar^2,3, Georgina Terroso², Romana Vieira¹, Diana Gonçalves⁴, Tiago Meirinhos⁵, Teresa Martins-Rocha^2,3, Ana Águeda^3,5, Raquel Ferreira^2,3, Miguel Bernardes^2,3, Carlos Vaz^2,3, Raquel Lucas⁶ and Lúcia Costa², ¹Rheumatology, Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal, ²Rheumatology, Centro Hospitalar de São João, Oporto, Portugal, ³Faculty of Medicine, Oporto University, Oporto, Portugal, ⁴Rheumatology, Centro Hospitalar de Trás-os-Montes e Alto Douro, Vila Real, Portugal, ⁵Rheumatology, Centro Hospitalar do Baixo Vouga, Aveiro, Portugal, ⁶Public Health Institute of Oporto University, Oporto, Portugal
Background/Purpose: In Osteoporosis, hip fractures account for significant disease burden, with increased morbi-mortality and financial load on the patient and healthcare system. This study aimed…
Abstract Number: 2326 • 2018 ACR/ARHP Annual Meeting
Outcomes One Year after Hip Fracture Repair in the Elderly: Does Social Isolation Matter?
Lisa A. Mandl¹, Serena Lian¹, Jackie Szymonifka², Kirsten Grueter³, Aidan Hadad³ and Joseph Lane³, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Orthopaedic Surgery, Hospital for Special Surgery, New York, NY
Background/Purpose: Hip fractures are a serious public health issue with a significant population burden, especially among those over age 65. Social isolation—how integrated a patient…
Abstract Number: 2336 • 2018 ACR/ARHP Annual Meeting
Identification of Osteoporosis As a Reason for Vertebral Fractures in Patients with Rheumatoid Arthritis and Non-Inflammatory Musculoskeletal Diseases – a Comparison between Trabecular Bone Score (TBS) and Bone Mineral Density (BMD)
Bjoern Buehring¹, Xenofon Baraliakos¹, Julian Thomas² and Jürgen Braun¹, ¹Ruhr-University Bochum, Herne, Germany, ²Rheumazentrum Ruhrgebiet, Herne, Germany
Identification of osteoporosis as a reason for vertebral fractures in patients with rheumatoid arthritis and non-inflammatory musculoskeletal diseases – A comparison between trabecular bone score…
Abstract Number: 1144 • 2018 ACR/ARHP Annual Meeting
Risk of Osteoporotic Fractures in Patients with Rheumatoid Arthritis and End Stage Renal Disease. Findings from the Usrds Database
Renee Peterkin-McCalman, Jennifer Waller, Brian Le, Alyce Oliver, Evan Manning, Stanley Nahman and Laura Carbone, Medical College of Georgia at Augusta University, Augusta, GA
Background/Purpose: Rheumatoid arthritis (RA) and End Stage Renal Disease (ESRD) are independent risk factors for osteoporotic fractures. Approximately one percent of persons with ESRD have…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].